glp-1 ncbi Harnessing Receptor Agonists for Obesity Treatment: Prospects and Obstacles on the Horizon GLP−1 receptor agonists for the

By targeting both metabolic and neurodegenerative pathways, GLP-1 receptor agonists represent a multifaceted approach to PD treatment, offering hope for better disease management and improved patient outcomes

Third, integrating AI into clinical trials raises ethical concerns, including algorithmic bias, lack of explainability of decision-making, and risks of hallucinations or misdiagnoses that could negatively impact patient outcomes

If the application is forgotten A double dose should not be used if the previous dose is forgotten

Autism Spectrum Disorder (ASD) is a complex, multifactorial condition with wide-ranging symptoms and severities

Originally developed for Type 2 diabetes, it has proven effective for weight loss, leading to its approval for obesity management under the brand names Wegovy and Ozempic

Meta-analysis of randomized controlled trials of red meat consumption in comparison with various comparison diets on cardiovascular risk Factors